Teva charged in DoJ antitrust probe into generic drug price-fixing

Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice (DoJ) has announced.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pharma companies pay £255m to settle price-fixing charges

24 August 2023 Payments mark the sixth and seventh made to resolve price-fixing charges | Teva donates $50 million in drugs to humanitarian organisations.

Americas

Celgene, Teva execs grilled over price hikes

1 October 2020 A US House of Representatives committee has accused Teva and Celgene of imposing unjustified price hikes on blockbuster drugs Copaxone and Revlimid.

Americas

Judge gives initial approval to Actavis $20m antitrust deal

15 September 2020 A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Teva charged in DoJ antitrust probe into generic drug price-fixing

More on this story

Editor's picks

Editor's picks

More features